Over the past three months, shares of Bristol-Myers Squibb (NYSE: BMY) moved higher by 8.86%. Before having a look at the importance of debt, let us look at how much debt Bristol-Myers Squibb has.
Bristol-Myers Squibb’s Debt
According to the Bristol-Myers Squibb’s most recent financial statement as reported on November 5, 2020, total debt is at $44.95 billion, with $41.36 billion in long-term debt and $3.58 billion in current debt. Adjusting for $19.43 billion in cash-equivalents, the company has a net debt of $25.51 billion.
Let’s define some of the terms we used in the paragraph above. Current debt is the portion of a company’s debt which is due within 1 year, while long-term debt is the portion due in more than 1 year. Cash equivalents include cash and any liquid securities with maturity periods of 90 days or less. Total debt equals current debt plus long-term debt minus cash equivalents.
To understand the degree of financial leverage a company has, investors look at the debt ratio. Considering Bristol-Myers Squibb’s $125.54 billion in total assets, the debt-ratio is at 0.36. As a rule of thumb, a debt-ratio more than one indicates that a considerable portion of debt is funded by assets. A higher debt-ratio can also imply that the company might be putting itself at risk for default, if interest rates were to increase. However, debt-ratios vary widely across different industries. A debt ratio of 25% might be higher for one industry and average for another.
Importance Of Debt
Besides equity, debt is an important factor in the capital structure of a company, and contributes to its growth. Due to its lower financing cost compared to equity, it becomes an attractive option for executives trying to raise capital.
However, due to interest-payment obligations, cash-flow of a company can be impacted. Having financial leverage also allows companies to use additional capital for business operations, allowing equity owners to retain excess profit, generated by the debt capital.
Looking for stocks with low debt-to-equity ratios? Check out Benzinga Pro, a market research platform which provides investors with near-instantaneous access to dozens of stock metrics – including debt-to-equity ratio. Click here to learn more.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
